{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "COVID-19",
      "POC diagnostics",
      "lateral flow immunoassay",
      "nucleic acid later flow assay",
      "paper-based microfluidics",
      "paper-based-biosensor"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33917183",
  "DateCompleted": {
    "Year": "2021",
    "Month": "05",
    "Day": "05"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "11",
    "Day": "11"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "04",
        "Day": "07"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "110",
      "10.3390/bios11040110"
    ],
    "Journal": {
      "ISSN": "2079-6374",
      "JournalIssue": {
        "Volume": "11",
        "Issue": "4",
        "PubDate": {
          "Year": "2021",
          "Month": "Apr",
          "Day": "07"
        }
      },
      "Title": "Biosensors",
      "ISOAbbreviation": "Biosensors (Basel)"
    },
    "ArticleTitle": "Paper-Based Biosensors: Frontiers in Point-of-Care Detection of COVID-19 Disease.",
    "Abstract": {
      "AbstractText": [
        "This review summarizes the state of the art of paper-based biosensors (PBBs) for coronavirus disease 2019 (COVID-19) detection. Three categories of PBB are currently being been used for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnostics, namely for viral gene, viral antigen and antibody detection. The characteristics, the analytical performance, the advantages and drawbacks of each type of biosensor are highlighted and compared with traditional methods. It is hoped that this review will be useful for scientists for the development of novel PBB platforms with enhanced performance for helping to contain the COVID-19 outbreak, by allowing early diagnosis at the point of care (POC)."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [
          "0000-0001-8990-8506"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Chemistry and Drug Technologies, Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy."
          }
        ],
        "LastName": "Antiochia",
        "ForeName": "Riccarda",
        "Initials": "R"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Switzerland",
    "MedlineTA": "Biosensors (Basel)",
    "NlmUniqueID": "101609191",
    "ISSNLinking": "2079-6374"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antigens, Viral"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "RNA, Viral"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "analysis"
      ],
      "DescriptorName": "Antigens, Viral"
    },
    {
      "QualifierName": [
        "instrumentation",
        "methods"
      ],
      "DescriptorName": "Biosensing Techniques"
    },
    {
      "QualifierName": [
        "diagnosis",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "CRISPR-Cas Systems"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Immunoassay"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Paper"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Point-of-Care Systems"
    },
    {
      "QualifierName": [
        "analysis"
      ],
      "DescriptorName": "RNA, Viral"
    },
    {
      "QualifierName": [
        "genetics",
        "isolation & purification",
        "metabolism"
      ],
      "DescriptorName": "SARS-CoV-2"
    }
  ],
  "CoiStatement": "The author declares no conflict of interest."
}